SCHEMBL1508253

SCHEMBL1508253

COP(=O)(OC)C(c1ccc(F)cc1)(c1ccc(F)cc1)c1ccc(Cl)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
CYP19A1 P11511 2/20 0.39
SMN1; SMN2 Q16637 3/20 0.36
TSHR P16473 2/20 0.36
NPC1 O15118 1/20 0.36
TP53 P04637 1/20 0.36
RAB9A P51151 1/20 0.36
HSD17B10 Q99714 1/20 0.36
ENPP1 P22413 1/20 0.35
ENPP2 Q13822 1/20 0.35
ALOX15 P16050 1/20 0.35
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
MAPK1 P28482 1/20 0.34
HIF1A Q16665 1/20 0.34
POLB P06746 1/20 0.34
ADCY1 Q08828 1/20 0.34
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1507954 0.91 KCNN4 (0.36) CYP1A2CYP2C19SMN1; SMN2TSHRNPC1
SCHEMBL14066331 0.85 KCNN4 (0.40) CYP1A2CYP2C9CYP2C19CYP19A1SMN1; SMN2
SCHEMBL1508216 0.79 KCNN4 (0.45) CYP19A1SMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL1508011 0.76 KCNN4 (0.45) CYP1A2CYP2C9CYP2C19SMN1; SMN2TSHR
SCHEMBL1508145 0.75 KCNN4 (0.40) CYP19A1SMN1; SMN2NPC1RAB9AMAPT
SCHEMBL1508255 0.73 KMT2A (0.42) CYP1A2CYP2C9CYP2C19CYP19A1SMN1; SMN2
SCHEMBL1508091 0.72 HDAC6 (0.41) SMN1; SMN2NPC1RAB9AKMT2AMEN1
SCHEMBL13337662 0.72 CA1 (0.46) SMN1; SMN2NPC1TP53RAB9AHSD17B10
SCHEMBL13337670 0.72 ESR1 (0.43) TSHRHSD17B10KMT2AMEN1KDM4E
SCHEMBL13337686 0.71 KCNN4 (0.42) ALOX15KMT2AMEN1MAPK1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2292595-A1 Potassium channel modulators NeuroSearch AS (DK) 2011-03-09 EP claimed
US-7429618-B2 Potassium channel modulators NEUROSEARCH A/S (DK) 2008-09-30 US claimed
EP-1911740-A1 POTASSIUM CHANNEL MODULATORS NeuroSearch A/S (DK) 2008-04-16 EP claimed
US-20070161607-A1 Potassium channel modulators SANIONA A/S (DK) 2007-07-12 US claimed
US-20050009816-A1 Potassium channel modulators SANIONA A/S (DK) 2005-01-13 US claimed
EP-1465863-A1 POTASSIUM CHANNEL MODULATORS Poseidon Pharmaceuticals A/S (DK) 2004-10-13 EP claimed
WO-2003059873-A1 POTASSIUM CHANNEL MODULATORS POSEIDON PHARMACEUTICALS A/S (DK) 2003-07-24 WO claimed
EP-2292595-A1 Potassium channel modulators NeuroSearch AS (DK) 2011-03-09 EP disclosed
EP-2292595-A1 Potassium channel modulators NeuroSearch AS (DK) 2011-03-09 EP disclosed
US-7429618-B2 Potassium channel modulators NEUROSEARCH A/S (DK) 2008-09-30 US disclosed
US-7429618-B2 Potassium channel modulators NEUROSEARCH A/S (DK) 2008-09-30 US disclosed
US-7429618-B2 Potassium channel modulators NEUROSEARCH A/S (DK) 2008-09-30 US disclosed
EP-1911740-A1 POTASSIUM CHANNEL MODULATORS NeuroSearch A/S (DK) 2008-04-16 EP disclosed
US-20070161607-A1 Potassium channel modulators SANIONA A/S (DK) 2007-07-12 US disclosed
US-7208527-B2 Potassium channel modulators POSEIDON PHARMACEUTICALS A/S (DK) 2007-04-24 US disclosed
US-7208527-B2 Potassium channel modulators POSEIDON PHARMACEUTICALS A/S (DK) 2007-04-24 US disclosed
US-7208527-B2 Potassium channel modulators POSEIDON PHARMACEUTICALS A/S (DK) 2007-04-24 US disclosed
US-20050009816-A1 Potassium channel modulators SANIONA A/S (DK) 2005-01-13 US disclosed
EP-1465863-A1 POTASSIUM CHANNEL MODULATORS Poseidon Pharmaceuticals A/S (DK) 2004-10-13 EP disclosed
WO-2003059873-A1 POTASSIUM CHANNEL MODULATORS POSEIDON PHARMACEUTICALS A/S (DK) 2003-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009816-A1 Potassium channel modulators KCNC1, KCNQ1, KCNA1 CYP1A2 4017/4885CYP2C9 3646/4885CYP2C19 4308/4885
US-20070161607-A1 Potassium channel modulators KCNC1, KCNQ1, KCNA1 CYP1A2 4017/4885CYP2C9 3646/4885CYP2C19 4308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.